Alamar Biosciences Upsized IPO Closes

Alamar Biosciences, a company focused on Precision Proteomics for early disease detection, announced the closing of its upsized initial public offering. The offering involved 12,937,500 shares of common stock, including the full exercise of the underwriters' option, at $17.00 per share. This raised approximately $219.9 million in gross proceeds. The shares commenced trading on the Nasdaq Global Select Market on April 17, 2026, under the ticker symbol 'ALMR'. JPMorgan Chase===JPMorgan Chase, BofA Securities, Toronto-Dominion Bank===TD Cowen, SVB Leerink===Leerink Partners, and Stifel acted as joint book-running managers for the offering. Registration statements for these securities were filed with and became effective by the United States===United States Securities and Exchange Commission on April 16, 2026.